Table 1.

Baseline characteristics of study population

VariableOverall, n=488PAGP Value
Tertile 1, n=162Tertile 2, n=163Tertile 3, n=163
Age, yr64 (50–74)51 (37–63)69 (57–75)72 (59–78)<0.001
Sex: men/women (%)270/218 (55.3/44.7)86/70 (53.1/46.9)92/71 (56.4/43.6)92/71 (56.4/43.6)0.54
Prior CVD: yes/no (%)135/353 (27.7/72.3)23/139 (14.2/85.8)49/114 (30.1/69.9)63/100 (38.7/61.3)<0.001
Diabetes mellitus: yes/no (%)89/399 (18.2/81.8)15/147 (9.3/90.7)26/137 (16.0/84.0)48/115 (29.5/70.5)<0.001
Current smoker: yes/no (%)90/398 (18.4/81.6)37/125 (22.8/77.2)24/139 (14.7/85.3)29/134 (17.8/82.2)0.24
Body mass index, kg/m225.69 (22.99–29.06)25.20 (22.49–29.02)26.06 (23.15–29.06)25.51 (23.04–29.05)0.63
Systolic BP, mmHg135 (120–150)130 (120–150)139 (120–150)140 (122–160)<0.01
Diastolic BP, mmHg80 (70–85)80 (70–85)78 (70–84)80 (70–85)0.06
Hemoglobin, g/dl13.3 (12.1–14.5)14.3 (13.1–15.4)13.3 (12.0–14.3)12.5 (11.4–13.5)<0.001
Albumin, g/L44.8 (42.4–46.9)45.8 (43.4–47.3)45.2 (43.3–47.2)43.7 (41.4–45.9)<0.001
C-reactive protein, mg/L2 (1–6)1 (1–5)2 (1–4)3 (1–7)0.004
Cholesterol, mg/dl178 (152–205)184 (160–206)181 (156–207)165 (142–188)<0.001
LDL, mg/dl85 (66–111)91 (71–115)85 (68–114)78 (61–100)0.004
HDL, mg/dl57 (47–72)60 (50–77)57 (47–70)56 (45–70)0.03
Calcium, mg/dl9.6 (9.2–9.9)9.5 (9.2–9.9)9.6 (9.3–10.0)9.6 (9.2–9.9)0.57
Phosphate, mg/dl3.3 (2.9–3.8)3.1 (2.7–3.5)3.2 (2.9–3.6)3.6 (3.2–4.2)<0.001
Parathormone, ng/L23.5 (12.5–51.4)14.1 (5.2–23.6)23.8 (14.3–47.7)46.0 (22.9–79.3)<0.001
Creatinine, mg/dl1.78 (1.26–2.43)1.15 (0.97–1.52)1.75 (1.42–2.13)2.51 (2.01–3.50)<0.001
eGFR, ml/min per 1.73 m235 (23–56)66 (44–81)35 (27–45)22 (15–28)<0.001
Therapy with ACEI/ARB: yes/no (%)345/143 (70.7/29.3)113/49 (69.8/31.2)116/47 (71.2/28.8)116/47 (71.2/28.8)0.78
Therapy with statins: yes/no (%)236/252 (48.4/51.6)59/103 (36.4/63.6)90/73 (55.2/44.8)87/76 (53.4/46.6)0.002
Therapy with 25-OH vitamin D: yes/no (%)89/399 (18.2/81.8)15/147 (9.3/90.7)28/135 (17.2/82.8)46/117 (28.2/71.8)<0.001
Therapy with phosphate binder: yes/no (%)133/355 (27.3/72.7)23/139 (14.2/85.8)36/127 (22.1/77.9)74/89 (45.4/54.6)<0.001
PAG, μM6.21 (2.99–13.18)1.96 (1.06–2.97)6.20 (4.93–7.83)17.09 (13.14–27.51)<0.001
  • Data are expressed as means (SDs) or medians (IQRs) as appropriate. Differences between tertiles were tested using Kruskal–Wallis or chi-squared test as appropriate. CVD, cardiovascular disease; ACEI, angiotensin–converting enzyme inhibitor; ARB, angiotensin receptor blocker; 25-OH vitamin D, 25-hydroxyvitamine D.